Deciphering the complex role of thrombospondin-1 in glioblastoma development.

Fiche publication


Date publication

mars 2019

Journal

Nature communications

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DEDIEU Stéphane


Tous les auteurs :
Daubon T, Léon C, Clarke K, Andrique L, Salabert L, Darbo E, Pineau R, Guérit S, Maitre M, Dedieu S, Jeanne A, Bailly S, Feige JJ, Miletic H, Rossi M, Bello L, Falciani F, Bjerkvig R, Bikfalvi A

Résumé

We undertook a systematic study focused on the matricellular protein Thrombospondin-1 (THBS1) to uncover molecular mechanisms underlying the role of THBS1 in glioblastoma (GBM) development. THBS1 was found to be increased with glioma grades. Mechanistically, we show that the TGFβ canonical pathway transcriptionally regulates THBS1, through SMAD3 binding to the THBS1 gene promoter. THBS1 silencing inhibits tumour cell invasion and growth, alone and in combination with anti-angiogenic therapy. Specific inhibition of the THBS1/CD47 interaction using an antagonist peptide decreases cell invasion. This is confirmed by CD47 knock-down experiments. RNA sequencing of patient-derived xenograft tissue from laser capture micro-dissected peripheral and central tumour areas demonstrates that THBS1 is one of the gene with the highest connectivity at the tumour borders. All in all, these data show that TGFβ1 induces THBS1 expression via Smad3 which contributes to the invasive behaviour during GBM expansion. Furthermore, tumour cell-bound CD47 is implicated in this process.

Mots clés

Animals, Brain Neoplasms, blood supply, CD47 Antigen, antagonists & inhibitors, Cell Line, Tumor, Cerebral Cortex, Gene Expression Regulation, Neoplastic, Glioblastoma, blood supply, Humans, Laser Capture Microdissection, Male, Mice, Mice, Knockout, Neoplasm Invasiveness, Peptides, pharmacology, Promoter Regions, Genetic, Protein Binding, RNA, Small Interfering, genetics, Signal Transduction, Smad3 Protein, genetics, Spheroids, Cellular, metabolism, Survival Analysis, Thrombospondin 1, antagonists & inhibitors, Transforming Growth Factor beta1, genetics, Xenograft Model Antitumor Assays

Référence

Nat Commun. 2019 Mar 8;10(1):1146